Fig. 1From: Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreementNICE guidance timeline prior to MAA initiation. HST, Highly specialised technology; MAA, managed access agreement; NICE, National Institute for Health and Care ExcellenceBack to article page